{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:45Z","timestamp":1793982285609,"version":"4.8.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41409-026-03004-x","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:11:15Z","timestamp":1786191075000},"page":"1555-1557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated plasma anandamide levels in sclerotic chronic graft-versus-host disease highlight the endocannabinoid system as a potential therapeutic target"],"prefix":"10.1038","volume":"61","author":[{"given":"Sencer","family":"Goklemez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-9354","authenticated-orcid":false,"given":"Steven Z.","family":"Pavletic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoyoung","family":"Choo-Wosoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-0211","authenticated-orcid":false,"given":"Filip","family":"Pirsl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-4592","authenticated-orcid":false,"given":"Eduard","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seray Berfin","family":"Karagoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resat","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-9655","authenticated-orcid":false,"given":"Najla","family":"El Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"3004_CR1","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1097\/TP.0000000000005345","volume":"109","author":"N El Jurdi","year":"2025","unstructured":"El Jurdi N, Blazar BR, Pavletic SZ. Chronic graft-versus-host disease, Part 2: clinical success and roadmap to the future. Transplantation. 2025;109:e446\u2013e54.","journal-title":"Transplantation"},{"key":"3004_CR2","first-page":"5098","volume":"121","author":"Y Inamoto","year":"2013","unstructured":"Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood J Am Soc Hematol. 2013;121:5098\u2013103.","journal-title":"Blood J Am Soc Hematol"},{"key":"3004_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107477","volume":"208","author":"R Cinar","year":"2020","unstructured":"Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB1R antagonists. Pharm Ther. 2020;208:107477.","journal-title":"Pharm Ther"},{"key":"3004_CR4","doi-asserted-by":"crossref","unstructured":"Cinar R, Gochuico BR, Iyer MR, Jourdan T, Yokoyama T, Park JK, et al. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight. 2017;2:e92281.","DOI":"10.1172\/jci.insight.92281"},{"key":"3004_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1164\/rccm.202406-1143RL","volume":"211","author":"R Cinar","year":"2025","unstructured":"Cinar R, Basu A, Arif M, Park JK, Zawatsky CN, Zuo BLG, et al. Anandamide is a potential blood biomarker of Hermansky-Pudlak syndrome pulmonary fibrosis. Am J Respir Crit Care Med. 2025;211:650\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"3004_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.471","volume":"11","author":"R Cinar","year":"2021","unstructured":"Cinar R, Park JK, Zawatsky CN, Coffey NJ, Bodine SP, Abdalla J, et al. CB1R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky\u2013Pudlak syndrome. Clin Transl Med. 2021;11:e471.","journal-title":"Clin Transl Med"},{"key":"3004_CR7","doi-asserted-by":"crossref","unstructured":"Basu A, Arif M, Wolf KM, Behee M, Johnson N, Pommerolle L, et al. Targeting cannabinoid receptor 1 for antagonism in pro-fibrotic alveolar macrophages mitigates pulmonary fibrosis. JCI Insight. 2025;10:e187967.","DOI":"10.1172\/jci.insight.187967"},{"key":"3004_CR8","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u201379.","journal-title":"N Engl J Med"},{"key":"3004_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.amjms.2025.06.003","volume":"370","author":"A Basu","year":"2025","unstructured":"Basu A, Pommerolle L, Arif M, Meliton AY, Udofia I, Wu D, et al. Elevated blood anandamide levels in acute COVID-19 pneumonia with respiratory failure. Am J Med Sci. 2025;370:271\u20137.","journal-title":"Am J Med Sci"},{"key":"3004_CR10","first-page":"1241","volume":"137","author":"CY Yuan","year":"2021","unstructured":"Yuan CY, Zhou V, Sauber G, Stollenwerk T, Komorowski R, L\u00f3pez A, et al. Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease. Blood J Am Soc Hematol. 2021;137:1241\u201355.","journal-title":"Blood J Am Soc Hematol"},{"key":"3004_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ajh.25717","volume":"95","author":"S Goklemez","year":"2020","unstructured":"Goklemez S, Im AP, Cao L, Pirsl F, Steinberg SM, Curtis LM, et al. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis. Am J Hematol. 2020;95:387\u201394.","journal-title":"Am J Hematol"},{"key":"3004_CR12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S2213-8587(25)00216-5","volume":"13","author":"FK Knop","year":"2025","unstructured":"Knop FK, Kunos G, Dicker D, Paquette JS, Aronne L, Frenkel O, et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Lancet Diab Endocrinol. 2025;13:911\u201323.","journal-title":"Lancet Diab Endocrinol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03004-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03004-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03004-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:41Z","timestamp":1793978861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03004-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3004"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03004-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the institutional review board of the National Cancer Institute, National Institutes of Health (approved on 8\/16\/2004, study number 04C0281) and was conducted according to the Declaration of Helsinki. All patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}